These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27594167)

  • 1. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers.
    Cicero TJ; Ellis MS; Kasper ZA
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):56-62. PubMed ID: 27594167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse and diversion.
    Nalamachu SR; Shah B
    Postgrad Med; 2022 May; 134(4):388-394. PubMed ID: 30025214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.
    Iwanicki JL; Severtson SG; McDaniel H; Rosenblum A; Fong C; Cicero TJ; Ellis MS; Kurtz SP; Buttram ME; Dart RC
    PLoS One; 2016; 11(12):e0167499. PubMed ID: 27936038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.
    Cassidy TA; Oyedele N; Mickle TC; Guenther S; Budman SH
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1071-1082. PubMed ID: 28771942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
    Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
    Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
    Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
    Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.
    Friedmann N; Marsman MR; de Kater AW; Burns LH; Webster LR
    J Opioid Manag; 2018; 14(6):437-443. PubMed ID: 30629280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro approach for evaluating the oral abuse deterrence of solid oral extended-release opioids with properties intended to deter abuse via chewing.
    Externbrink A; Sharan S; Sun D; Jiang W; Keire D; Xu X
    Int J Pharm; 2019 Apr; 561():305-313. PubMed ID: 30862508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of extended-release opioid analgesics for the treatment of chronic pain.
    Gudin JA
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):49-61. PubMed ID: 23527669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids.
    Devarakonda K; Kostenbader K; Zheng Y; Montgomery JB; Barrett T; Young JL; Webster LR
    Postgrad Med; 2015 Jan; 127(1):13-21. PubMed ID: 25584931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation.
    Ellis MS; Cicero TJ; Dart RC; Green JL
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):117-121. PubMed ID: 30411819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.
    Butler SF; Black R; Grimes Serrano JM; Folensbee L; Chang A; Katz N
    Pain Med; 2010 Jan; 11(1):81-91. PubMed ID: 20002324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse risks and routes of administration of different prescription opioid compounds and formulations.
    Butler SF; Black RA; Cassidy TA; Dailey TM; Budman SH
    Harm Reduct J; 2011 Oct; 8():29. PubMed ID: 22011626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).
    Vosburg SK; Beaumont J; Dailey-Govoni ST; Butler SF; Green JL
    Pain Med; 2020 Sep; 21(9):1891-1901. PubMed ID: 31617931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.